Physician profile
Jack William Cramer
NPI 1134331440
$5,718.55
in general payments reported to CMS, 2019-2025
39 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,537 · 2020: $1,692 · 2021: $1,283 · 2022: $343 · 2023: $142 · 2024: $240 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $622.58 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $490.26 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $428.21 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $422.56 | 2019-2025 | Xifaxan |
| Abbvie INC. | $402.27 | 2019-2025 | |
| Lilly USA, LLC | $398.28 | 2019-2023 | Emgality, Jardiance |
| Allergan, INC. | $365.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $296.55 | 2019-2025 | Airsupra |
| Glaxosmithkline, LLC. | $267.63 | 2019-2023 | Arexvy, Shingrix |
| Dexcom, INC. | $227.45 | 2022-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $203.92 | 2020-2021 | |
| Amgen INC. | $191.27 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.89 | 2019-2023 | Vyvanse |
| Janssen Pharmaceuticals, INC | $151.27 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.67 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Cramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.